Overview

• The company’s 38-for-1 stock split on June 16 triggered a record 434% one-day share increase and multiple trading halts.
• Regencell has generated no revenue since its 2021 Nasdaq debut and posted a $4.4 million loss for the fiscal year ending June 2024.
• Only about 6% of nearly 500 million outstanding shares are available to trade, amplifying volatility in response to market moves.
• CEO Au Yat-Gai and other insiders hold roughly 86% of shares, leaving minimal stock for public investors.
• The firm remains in the R&D stage developing traditional Chinese medicine treatments for neurological disorders after unreviewed 2022 COVID-19 trials.